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Center, Nijmegen, The NetherlandsABSTRACT ATP can be produced in the cytosol by glycolytic conversion of glucose (GLC) into pyruvate. The latter can be
metabolized into lactate, which is released by the cell, or taken up by mitochondria to fuel ATP production by the tricarboxylic
acid cycle and oxidative phosphorylation (OXPHOS) system. Altering the balance between glycolytic and mitochondrial ATP
generation is crucial for cell survival during mitoenergetic dysfunction, which is observed in a large variety of human disorders
including cancer. To gain insight into the kinetic properties of this adaptive mechanism we determined here how acute (30 min)
inhibition of OXPHOS affected cytosolic GLC homeostasis. GLC dynamics were analyzed in single living C2C12 myoblasts
expressing the fluorescent biosensor FLII12Pglu-700md6 (FLII). Following in situ FLII calibration, the kinetic properties of GLC
uptake (V1) and GLC consumption (V2) were determined independently and used to construct a minimal mathematical model
of cytosolic GLC dynamics. After validating the model, it was applied to quantitatively predict V1 and V2 at steady-state
(i.e., when V1 ¼ V2 ¼ Vsteady-state) in the absence and presence of OXPHOS inhibitors. Integrating model predictions with exper-
imental data on lactate production, cell volume, and O2 consumption revealed that glycolysis and mitochondria equally
contribute to cellular ATP production in control myoblasts. Inhibition of OXPHOS induced a twofold increase in Vsteady-state
and glycolytic ATP production flux. Both in the absence and presence of OXPHOS inhibitors, GLC was consumed at near
maximal rates, meaning that GLC consumption is rate-limiting under steady-state conditions. Taken together, we demonstrate
here that OXPHOS inhibition increases steady-state GLC uptake and consumption in C2C12 myoblasts. This activation fully
compensates for the reduction in mitochondrial ATP production, thereby maintaining the balance between cellular ATP supply
and demand.INTRODUCTIONGlucose (GLC) is among the prime substrates for cellular en-
ergy production and serves as a precursor for various biomol-
ecules such as glycoproteins and glycolipids. Hence, the
capacity of a cell for GLC uptake and conversion greatly im-
pacts on its energetic and functional state. GLC uptake is
mediated by specific facilitative GLC transporters (Gluts).
These integral plasma membrane (PM) proteins belong to
the solute carrier 2A subfamily, which consists of 14
different members that differ in their substrate specificity,
transport kinetics, tissue distribution, and mode of regula-
tion. The rate of Glut-mediated cellular GLC uptake depends
on the amount of active Gluts on the PM, their kinetic prop-
erties, and the magnitude of the trans-PM glucose gradient,
which co-depends on the extracellular free GLC concentra-
tion ([GLC]ext) and the cytosolic free GLC concentration
([GLC]c). Once taken up, GLC is phosphorylated by the
glycolysis enzyme hexokinase (HK) to form glucose-6-phos-
phate (G6P). Subsequently, G6P is converted into pyruvateSubmitted April 10, 2015, and accepted for publication August 3, 2015.
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0006-3495/15/10/1372/15(PYR) and imported into mitochondria to fuel the tricarbox-
ylic acid (TCA) cycle. The latter produces NADH (reduced
nicotinamide adenine dinucleotide) and FADH2 (reduced
flavin adenine nucleotide), which serve as substrates for the
mitochondrial oxidative phosphorylation (OXPHOS) sys-
tem. Alternatively, PYR can be reversibly converted into
lactate (LAC) by lactate dehydrogenase that is released by
the cell into the extracellular medium. The OXPHOS system
consists of five multiprotein complexes (CI-CV) that
generate ATP by chemiosmotic coupling (1). CI-CIV consti-
tute the electron transport chain that extracts electrons from
NADH (at CI) and FADH2 (at CII). Subsequently, the elec-
trons are transported to CIII and from thereon to CIV where
they react with molecular oxygen (O2). At CI, CIII and CIV
protons (Hþ) are transported from the mitochondrial matrix
across the mitochondrial inner membrane to generate an
inward-directed proton-motive force (PMF). Driven by the
PMF, controlled Hþ back-flux via CV (i.e., the FoF1-ATP
synthase) is used to synthesize ATP from ADP and inorganic
phosphate (Pi). ATP is generated by GLC breakdown during
glycolysis (2 ATP per GLC molecule), by the TCA cycle
(2 ATP per GLC molecule) and by the OXPHOS systemhttp://dx.doi.org/10.1016/j.bpj.2015.08.002
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these systems to cellular ATP production depends on many
parameters including the cell type and the nature/availability
of energy substrates. In practice, the actual number of ATP
molecules generated probably lies within the range of 29–
30 ATP molecules per oxidized GLC molecule (2).
In case of mitochondrial dysfunction, increased extra-
cellular LAC levels were observed in fibroblasts from
patients with mitochondrial disease (3), mouse embryonic
fibroblasts (MEFs) from NDUFS4/ mice with isolated
CI deficiency (4), skin fibroblasts from patients with
myoclonic epilepsy with ragged red fibers syndrome (5),
myotubes overexpressing the mitochondrial uncoupling
protein 3 (6), polymerase gamma mutator mice (7), and hu-
man embryonic kidney 293 cells with a knockdown of the
CI subunit NDUFS3 (8). In addition, drug-induced mito-
chondrial dysfunction stimulated GLC uptake in Clone 9
cells (9–13) and Glut1 upregulation and enhanced GLC
uptake was shown in cancer cells (14,15). These results sug-
gest that glycolysis-mediated ATP generation is activated
by mitochondrial dysfunction (5). Currently, the balance
and interactions between GLC uptake, glycolysis- and
OXPHOS-mediated ATP production, as well as their regula-
tion, is a subject of intense study (16–20). However, the
various components of this dynamic system cannot be
simultaneously accessed by experimental studies in single
living cells. This necessitates the use of mathematical
models (21–27).
In this study, we aimed to demonstrate how acute
OXPHOS dysfunction affects steady-state GLC uptake
and consumption, LAC production, O2 consumption, and
ATP production in C2C12 myoblasts. To this end we inte-
grated experimental results with in silico predictions of a
minimal model of GLC dynamics. This model correctly pre-
dicted the glycolytic flux in control and OXPHOS-inhibited
cells and revealed that glycolysis and mitochondria equally
contribute to ATP production when OXPHOS is active. We
observed that acute OXPHOS inhibition twofold increases
GLC uptake and consumption, thereby fully compensating
for the loss in OXPHOS-mediated ATP generation and
maintaining steady-state ATP homeostasis.MATERIALS AND METHODS
Chemicals
Sodium iodoacetic acid (IAA), cytochalasin B (CytoB), cytochalasin D
(CytoD), antimycin A (AA), and p-trifluoromethoxy carbonyl cyanide
phenyl hydrazone were obtained from Sigma-Aldrich (Zwijndrecht, The
Netherlands). Piericidin A (PA) was obtained from Enzo Life Sciences
(Raamsdonksveer, The Netherlands).Cell culture
C2C12 myoblasts were cultured at 37C (95% air, 5% CO2) in Dulbecco’s
modified eagle’s medium (DMEM-32430; Life Technologies – Invitrogen,Bleiswijk, The Netherlands), supplemented with 10% (v/v) fetal bovine
serum (FBS). C2C12 myoblasts were seeded in fluorodishes (#FD35-100,
World Precision Instruments, Sarasota, FL) at a density of 40,000 cells/dish.Transfection
1 day after seeding, C2C12 cells were at 40% confluence. 1 mg DNA was
mixed with 6 ml lipofectamine (Invitrogen) in 0.5 ml FBS-free DMEM.
Following 20 min incubation at room temperature the transfection mix
was added to the cells in FBS-free DMEM. After 6 h this medium was re-
placed by DMEM containing 10% FBS. The glucose sensor FLII12Pglu-
700md6 (FLII) (Addgene Plasmid #17866; (28)) and its high affinity variant
FLIPglu-170nd13V (Addgene Plasmid #18018; (29)) were a gift from
Dr. Wolf Frommer (Department of Plant Biology, Carnegie Institution for
Science, Stanford, CA).Single cell microscopy of cytosolic GLC
dynamics
At 24 h posttransfection the C2C12 myoblasts were at 80% confluence.
Cells were washed and incubated for 3 min in HEPES/Tris (HT) buffer
(adjusted to pH 7.4 with Tris) containing 4.2 mM KCl, 132 mM NaCl,
10 mM HEPES, 1.2 mM MgCl2, and 1 mM CaCl2. The HT buffer was
then replaced with HT buffer containing 500 mM IAA and incubated for
another 15 min. Subsequently the fluorodish was mounted onto an inverted
microscope (30) (Axiovert 200M, Carl Zeiss BV, Sliedrecht, The
Netherlands), equipped with a 40/1.3 NA Plan NeoFluar objective (Carl
Zeiss) and a CoolSNAP HQ monochrome charge-coupled device (CCD)-
camera (Roper Scientific, Vianen, The Netherlands). Microscopy hardware
was controlled using Metafluor 6.0 software (Universal Imaging, Downing-
town, PA). FLII and FLIPglu-170nd13V were excited at 430 nm (CFP) for
300 ms using a Polychrome IV monochromator system (TILL Photonics,
Gra¨felfing, Germany). CFP fluorescence was detected using a 455DRLP
dichroic mirror (XF2034, Omega Optical Inc, Brattleboro, VT) and a
480AF30 (XF3075; Omega) emission filter. Citrine emission (CitrineFRET)
was measured using 430 nm excitation light (during 200 ms) and emission
was detected using the 455DRLP dichroic mirror and a 535AF26 emission
filter (XF3079; Omega). Time-lapse recordings were performed using an
acquisition interval of 2.5 s.LAC measurements
C2C12 myoblasts were seeded in a T25 culture flask and cultured for 1 day,
as described above. Cells were then incubated in 1 ml HT buffer containing
2 mM GLC and either vehicle or mitochondrial inhibitors for 60–90 min.
The buffer was collected and centrifuged for 5 min at 600  g. LAC levels
were quantified using an Architect chemical analyzer (Abbott B.V., Hoofd-
dorp, The Netherlands). For each sample, the cell number was determined
using a Burker Turk hemocytometer.O2 consumption measurements
For respirometry analysis (31) C2C12 myoblasts were counted using a
Scepter cell counter (Millipore, Billerica, MA) and 1.5  106 cells were
transferred to the temperature-controlled (37C) chamber of an Oxy-
graph-2k controlled by Datlab 5 recording (2 s time interval) and analysis
software (32) (Oroboros Instruments, Innsbruck, Austria). To measure O2
consumption, cells were either resuspended in HT buffer containing
2 mM GLC or culture medium. After adding the cells to the respiration
chamber, the O2 consumption trace was allowed to stabilize for 10 min until
routine respiration could be measured in the coupled state of respiratory
control. The complex V (CV) inhibitor oligomycin A (2.5 mM) was then
added to determine the leak respiration. The maximal capacity of theBiophysical Journal 109(7) 1372–1386
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tion with the mitochondrial uncoupler p-trifluoromethoxy carbonyl cyanide
phenyl hydrazone. Finally, minimal respiration (ROX value) was assessed
after adding a maximal concentration of the complex I (CI) inhibitor rote-
none (0.5 mM) and of the complex III (CIII) inhibitor antimycin A (AA;
0.5 mM). This ROX value was subtracted from the other respiratory rates
to correct for nonmitochondrial respiration.Cellular ATP level measurements
The total cellular ATP level was measured after 24 h using an ATP biolu-
minescence assay kit according to the manufacturer’s protocol (CLS II;
Roche Applied Science, Mannheim, Germany). Briefly, cells were har-
vested and counted using a Scepter cell counter (Millipore) after which
cellular ATP was released by adding the cell suspension to a boiling Tris-
EDTA buffer (100 mM Tris, 4 mM EDTA, pH 7.75) for 2 min. Part of
this solution was diluted 1:1 (v/v) with luciferase reagent, followed by mea-
surement of the bioluminescence signal. ATP concentrations were calcu-
lated using a standard curve, and divided by cell count to obtain ATP values.Image processing, statistical analysis, and
mathematical modeling
Microscopy images were stored in native Metafluor format (Universal Im-
aging, Bedford Hills, NY) and analyzed off-line using Image Pro Plus 6.1
software (Media Cybernetics, Rockville, MD). Individual images were
background corrected for each wavelength by subtracting the average inten-
sity in an extracellular region of interest (ROI). Next, cell-derived fluores-
cence signals were quantified using cytosolic circular ROIs. Average values
are presented as mean5 SE. Curve fitting and statistical analysis was per-
formed using Origin Pro 6.1 (OriginLab, Northampton, MA) and GraphPad
Prism 5 (Graphpad Software, La Jolla, CA). Unless stated otherwise, statis-
tical significance was assessed using an unpaired Student’s t-test and
expressed as ***p < 0.001, **p < 0.01, and *p < 0.05 relative to the indi-
cated condition. Mathematical modeling was performed using MATLAB/
Simulink 6.1 (The MathWorks, Natick, MA).RESULTS
In situ calibration of the FLII GLC sensor in C2C12
myoblasts
In this study, we used the GLC biosensor FLII (28), which
is based on the fluorescence resonance energy transfer
(FRET) principle, to monitor dynamic changes in free cyto-
solic GLC concentration ([GLC]c). FLII consists of a GLC
binding domain sandwiched between CFP and the yellow
fluorescent protein mutant Citrine. The GLC binding
domain is derived from a periplasmic protein expressed in
Escherichia coli (33). When GLC binds, the emission of
Citrine upon CFP excitation (CitrineFRET) increases. Simul-
taneously, the CFP emission upon CFP excitation (CFP) will
decrease (Fig. 1 A). GLC unbinding will induce the reverse
effect and the emission ratio (CitrineFRET/CFP) can be used
as a readout of [GLC]c. Manipulation of [GLC]c by chang-
ing the extracellular [GLC] [GLC]ext (see next section for
details) induced antiparallel changes in CitrineFRET and
CFP in FLII-expressing C2C12 myoblasts (Fig. 1 B, upper
panel). No alterations in cellular volume upon [GLC]ext
manipulation were observed, as indicated by the lack of par-Biophysical Journal 109(7) 1372–1386allel changes in the individual CFP and CitrineFRET emis-
sion signals (Fig. 1 B, upper panel). Inspection of the
CitrineFRET/CFP signal revealed identical dynamic emission
ratio in different subcellular ROIs (Fig. 1 A, inset) and the
whole cell (Fig. 1 B, lower panel). For quantitative analysis
and mathematical modeling of [GLC]c dynamics, calibra-
tion of the FLII emission ratio is required. Using a cell per-
meabilization strategy with b-Escin (a triterpenoid saponin)
was not useful because it induced a shift in FLII signals
(data not shown), as reported previously for C2C12 cells
(34). Therefore the in situ calibration curve was generated
by incubating FLII-expressing C2C12 myoblasts with
different [GLC]ext concentrations in the presence of the
GLC consumption inhibitor IAA (500 mM). IAA inhibits
the glycolysis enzyme glyceraldehyde 3-phosphate dehy-
drogenase leading to G6P accumulation and allosteric HK
inhibition (35). Following a 30 min incubation with var-
ious [GLC]ext and IAA, the FLII emission ratio was stable
(Fig. 1 C). This shows that [GLC]ext and [GLC]c are fully
equilibrated, allowing calibration of the FLII emission ra-
tio (35). For each [GLC]ext the measured (CitrineFRET/
CFP) emission ratio was corrected for the emission ratio
obtained in the absence of extracellular GLC (CitrineFRET/
CFP0 mMGLC). This corrected emission ratio was termed
Rcorr. The experimental in situ calibration curve was fitted
using a Michaelis-Menten equation:
Rcorr ¼ Rmax  ½GLCc
Km þ ½GLCc
; (1)
with [GLC]c in mM, Rcorr equaling the corrected FLII
emission ratio (as defined above) and Km representing the
in situ FLII glucose affinity (in mM). Fitting yielded a
maximal FLII emission ratio (Rmax) of 3.6 5 0.4 and a
Km of 1.9 5 0.5 mM (Fig. 1 D). To allow calculation of
[GLC]c(t) from the measured Rcorr(t), Eq.1 was rearranged
into:
½GLCcðtÞ ¼
Km  RcorrðtÞ
Rmax  RcorrðtÞ: (2)
Analysis of GLC uptake and consumption in
C2C12 myoblasts
In the most simple case, (Fig. 2 A) dynamic changes in
[GLC]c (i.e. [GLC]c(t)) depend on the rate of GLC entry
(V1) across the PM and the rate of GLC consumption in
the cell (V2):
d½GLCc
dt
¼ V1  V2: (3)
Cellular GLC entry is mediated by Gluts (36). Quantitative
polymerase chain reaction (Q-PCR) analysis revealed that
Glut isoform 1 (37) is highly expressed in C2C12 myo-
blasts, whereas Glut2, Glut3, and Glut4 were not detected
FIGURE 1 In situ calibration of the glucose
sensor. (A) The glucose sensor FLII consists of a
GLC binding domain that is sandwiched between
CFP and Citrine. FRET increases and decreases
upon GLC binding and unbinding to the sensor,
respectively. The inset depicts a typical FLII-ex-
pressing C2C12 myoblast revealing the cytosolic
localization of the sensor (Citrine image shown).
ROIs used for temporal analysis of FLII fluores-
cence are marked by numerals. (B) Response of
FLII to a stepwise increase in extracellular GLC
([GLC]ext) in the presence of the GLC consump-
tion inhibitor IAA. The top panel shows the individ-
ual CitrineFRET (open symbols) and CFP (solid
symbols) average fluorescence intensity per pixel
(background corrected) for the two ROIs indicated
in (A). In addition, the average fluorescence inten-
sity per pixel (background corrected) for the total
cell was determined by creating a cellular mask
(binary image) of the cell and superimposing this
mask onto the background corrected image. Calcu-
lation of the FLII emission ratio (CitrineFRET/CFP)
revealed identical ratio-unit changes in all signals
(lower panel). (C) Stability of the FLII ratio signal
following 30 min incubation at various [GLC]ext in
the presence of 500 mM IAA. FLII images of
different cells were acquired. The mean Citrine-
FRET/CFP signal (5SD) of all cells within indi-
vidual images were plotted as a function of time
for 0.2, 2, and 7 mM [GLC]ext. For each concentra-
tion, no significant differences were detected be-
tween time points (one-way analysis of variance).
(D) Average CitrineFRET/CFP signal (5SE) as a
function of [GLC]ext (20 cells analyzed for each
[GLC]ext). Data were corrected by subtracting the
FLII emission ratio obtained at [GLC]ext ¼ 0. A
Michaelis-Menten equation was used to fit the
calibration curve (R2 ¼ 0.96). To see this figure in
color, go online.
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is dominated by Glut1-mediated GLC entry in our C2C12
myoblasts. To dissect the contribution of V1 and V2 in
determining [GLC]c, we adapted a strategy previously
described for cultured mouse astrocytes (35). Quantifica-
tion of V1 requires inhibition of GLC consumption, which
was achieved using IAA (Fig. 2 A). Conversely, GLC entry
was inhibited using cytochalasin B (CytoB) (Fig. 2 A), a
noncompetitive and membrane-permeable inhibitor of
Glut uniporters (17,33,35,38,39). CytoB inhibits GLC
transport by binding close to the GLC efflux site on the
cytoplasmic domain of Gluts (22,40). Control experiments
demonstrated that CytoB indeed blocked Glut-mediated
GLC influx in our cell system (Supporting Material B1
and Fig. S2 A). Removal of extracellular GLC induced a
drop in [GLC]c to zero within 3 min (Fig. 2 B), suggesting
that cytosolic GLC is actively consumed. When CytoB
treatment was carried out on IAA-pretreated cells, thedecrease in [GLC]c was blocked in a dose- and time-
dependent manner. It was found that 15 min pretreatment
with 500 mM IAA fully blocked GLC consumption
(Fig. 2 C). The experimental strategy to measure V1 in
C2C12 myoblasts is schematically summarized in Fig. 2
D and allows analysis of GLC entry under zero-trans con-
ditions (i.e., when [GLC]c is virtually zero before external
GLC re-addition). It consists of cell seeding and transfec-
tion (Fig. 2, Da and Db), optional treatment with a mito-
chondrial inhibitor (Fig. 2 Dc; see below), removal of
extracellular GLC (Fig. 2 Dd), IAA treatment (Fig. 2
De), and re-addition of external GLC (Fig. 2 Dg). In the
absence of IAA, increasing [GLC]ext from 0 to 2 mM
induced a biphasic increase in [GLC]c in GLC-depleted
myoblasts (Fig. 2, E and F, open symbols/bars) consisting
of a fast (V1,No-IAA) and slow component (V1slow,No-IAA).
In myoblasts preincubated with IAA (500 mM, 15 min)
the rate of fast [GLC]c increase (V1,IAA) was significantlyBiophysical Journal 109(7) 1372–1386
FIGURE 2 Experimental strategy for analysis of glucose uptake and consumption. (A) Principle of the approach. GLC enters from the extracellular
space ([GLC]ext) into the cytosol ([GLC]c) via facilitative Glut across the PM and is subsequently consumed. GLC enters at a rate V1 and is consumed
at a rate V2. CytoB and IAA (acting on HK) are used to inhibit V1 and V2, respectively. (B) Box plot of the average time required for lowering [GLC]c
to zero upon removal of [GLC]ext (n ¼ 10 cells; N ¼ 2 independent experiments). (C) Analysis of the concentration and duration of IAA treatment
required for full inhibition of GLC consumption. Graph presents the mean (5SE) of 15 cells per condition (N ¼ 3 independent experiments). Statistical
significance was determined using the Kruskal-Wallis test. (D) Flowchart of the experimental approach. After seeding and FLII transfection, cells are
optionally treated with mitochondrial inhibitors for 30 min. Subsequently, ([GLC]ext is removed and V2 is inhibited by IAA, followed by microscopy im-
aging. (E) Representative example of a GLC uptake experiment in the absence (solid symbols) and presence (open symbols) of IAA. After a 3 min in-
cubation in the absence of extracellular GLC, [GLC]ext was increased to 2 mM followed by addition of CytoB. Both in the absence and presence of
IAA, [GLC]c displayed a biphasic increase at rates V1,No-IAA and V1,IAA and V1slow,No-IAA and V1slow,IAA upon external GLC addition. The effect of CytoB
was reflected by the rates V2,No-IAA and V2,IAA. (F) Average values (5SD) for the various rates depicted in (E) (determined from linear regression analysis;
n ¼ 12 cells; N ¼ 3 independent experiments). #Not significantly different from zero determined by a one-way Student’s t-test. To see this figure in color,
go online.
1376 Liemburg-Apers et al.higher than V1,No-IAA, whereas the rate of increase of
the slow phase (V1slow,IAA vs. V1slow,No-IAA) was not
affected (Fig. 2, E and F). This shows that in the
absence of IAA, V1 is underestimated due to GLC con-
sumption, primarily during the fast phase. In the absence
of IAA, CytoB induced an acute drop in [GLC]c at a rate
V2,No-IAA (Fig. 2, E and F). In contrast, no significant
decrease in [GLCc] was observed (i.e., V2,IAA equaled
zero) when CytoB was added to IAA-treated cells
(Fig. 2, E and F). Supported by the results presented in
Fig. 2 C, these findings show that GLC is not consumed
in IAA-treated C2C12 cells. Applying Eq. 3 to the data
presented in Fig. 2 F suggests that 1) in the presence of
IAA: V2 z 0 so d[GLC]c/dt ¼ V1 ¼ V1,IAA ¼ 0.26 5
0.07(SD) mM/min, 2) in the absence of IAA, V1 is
underestimated by an amount of V2,No-IAA, so d[GLC]c/Biophysical Journal 109(7) 1372–1386dt ¼ V1,No-IAA þ V2,No-IAA ¼ 0.12 5 0.03(SD) þ
0.08 5 0.06(SD) ¼ 0.20 5 0.07(SD) mM/min. The fact
that V1,IAA is z V1,No-IAA þ V2,No-IAA strongly suggests
that the effect of IAA on V1 is due to inhibition of V2 rather
than an aspecific effect of this inhibitor on Glut1.Effect of mitochondrial inhibition on cellular GLC
uptake and consumption in C2C12 myoblasts
Using the strategy in Fig. 2 D, we next investigated the ef-
fect of short-term mitochondrial dysfunction on cellular
GLC uptake and consumption. To this end, cells were incu-
bated with mitochondrial inhibitors for 30 min before
microscopy analysis. In these experiments PA was used to
inhibit complex I (CI) of the OXPHOS system. In parallel
experiments, cells were treated with AA to inhibit OXPHOS
Glucose Flux and Mitoenergetic Function 1377CII. Respirometry analysis revealed that both inhibitors
dose-dependently inhibited CI and CIII (Fig. S3). Full inhi-
bition of mitochondrial O2 consumption in intact C2C12
cells required a minimal concentration of 100 nM PA
(IC50 ¼ 8.4 5 0.2 nM) and 20 nM AA (IC50 ¼ 8.5 5
0.2 nM). These concentrations were used during the
remainder of the study. First, we quantified the effect of
30 min mitochondrial inhibition on the maximal rate of
GLC entry for various [GLC]ext in IAA-treated cells
(Fig. 3 A). This was performed by calculating the maximal
linear rate of [GLC]c increase from single-cell recordings
(Fig. 3 B), which increased as a function of [GLC]ext in
vehicle-, PA-, and AA-treated cells (Fig. 3 C). Curve fitting
using a Hill equation revealed that the V1-associated Km
value (Fig. 3 D; Table 1, A1) and cooperativity factor
n (Fig. 3 E) were not affected in PA- and AA-treated
cells. In contrast, inhibitor-treated cells displayed a
large increased in maximal value of V1 (V1,max) (Fig. 3 F;
Table 1, A1).
We then analyzed the resting [GLC]c and the maximal
linear rate of [GLC]c decrease upon acute CytoB treat-
ment (Fig. 4, A and B). In the literature a Km value ofFIGURE 3 Effect of mitochondrial inhibition on cellular glucose uptake kineti
uptake (V1). (B) Typical GLC uptake in cells pretreated with vehicle, PA, or AA f
measure of V1. (C) Mean (5SE) of the maximal rate of [GLC]c increase as a fu
(n¼ 20 cells per condition; N¼ 4 independent experiments). A Hill equation wa
(D) Average value (5SD) of Km for vehicle-, PA-, or AA-treated cells. (E) Simi
now for Vmax. To see this figure in color, go online.60 mM was reported for HK (21,41). Because the
steady-state value of [GLC]c was 7- to 10-fold higher
than this value, we considered the maximal linear rate
of [GLC]c decrease upon acute CytoB treatment to reflect
the maximal value of V2 (V2,max). Inhibitor treatment did
not significantly alter the resting [GLC]c at 2 mM
[GLC]ext (Fig. 4 C; Table 1, A3), whereas V2,max was
1.8- and 2.5-fold higher in PA- and AA-treated cells,
respectively (Fig. 4 D; Table 1, A2). Taken together, our
results show that inhibition of CI and CIII increase the
maximal rates of cellular GLC uptake (V1,max) and con-
sumption (V2,max) within 30 min.A minimal mathematical model for GLC uptake
and consumption in C2C12 myoblasts
To gain insight into how V1 and V2 quantitatively contribute
to the kinetics of the [GLC]c signal, we developed a mathe-
matical model starting from Eq. 3. Because cellular volume
changes were not observed (see above), cell volume in the
model was assumed to be constant. Glut-mediated GLC
influx (V1) was modeled using an equation (41) that wascs. (A) Inhibition of the GLC consumption flux (V2) allows analysis of GLC
or 30 min. The maximal rate of linear increase of these curves was used as a
nction of [GLC]ext in vehicle-treated cells and cells treated with PA or AA
s used for curve fitting (Vehicle: R2¼ 0.85; PA: R2¼ 0.68; AA: R2¼ 0.94).
lar to (D), but now for the cooperativity parameter n. (F) Similar to (D), but
Biophysical Journal 109(7) 1372–1386
TABLE 1 Experimental results, model parameters and model predictions
Parameter Vehicle PA AA
A. Model Directly Based upon Experimental Parameters (Default Model)
1) GLC uptake rate (V1) parameters
a
Experimental Km,V1 (mM) 1.45 0.3 1.0 5 0.4 1.55 0.4
Experimental V1,max (mM/min) 0.325 0.05 2.8 5 0.7 2.95 0.5
2) GLC consumption rate (V2) parameters
b
Experimental V2,max (mM/min) 0.675 0.07 1.235 0.12 1.75 0.3
Km,V2 (mM) 0.06 0.06 0.06
3) [GLC]c at steady-state
Experimental (mM) 0.495 0.11 0.665 0.09 0.515 0.07
Predicted (mM) 0.02 0.40 0.20
B. Model with Adjusted V1,max (Optimal Model)
1) GLC uptake rate (V1) parameters
Adjusted V1,max (mM/min) 1.86 4.20 4.80
2) [GLC]c at steady-state
Predicted (mM) 0.49 0.66 0.51
3) GLC, PYR, LAC and ATP rates at steady-statec
Predicted V1 ¼ V2 ¼ Vsteady-state (mM/min) 0.60 1.14 1.50
Predicted PYR production rate V3 ¼ 2  Vsteady-state (mM/min) 1.20 2.28 3.00
Predicted rate of LAC release V7 ¼ V4 ¼ V3 (mM/min)d 1.20 2.28 3.00
Experimental rate of LAC release V7 (mM/min/cell) 1.85 0.6 (SD) 4.15 1.1 (SD) 3.55 1.6 (SD)
Predicted glycolytic ATP production rate 2  Vsteady-state (mM/min) 1.20 2.28 3.00
Experimental ATP-linked O2 consumption rate (mM/min) 0.435 0.08 (SD) 0 0
Experimental P/O ratio 2.75 0.4 (SD) n.d. n.d.
Predicted mitochondrial ATP production rate (mM/min) 1.25 0.2 (SD) 0 0
Predicted total ATP production (mM/min) 2.39 (100%) 2.28 (95%) 3.00 (126%)
Experimental total ATP (pmol/cell) 305 13 (SD) 195 5 (SD) 305 18 (SD)
All experiments and model predictions were performed at an extracellular free glucose concentration ([GLC]ext) of 2 mM. Statistics: errors reflect SEM,
unless stated otherwise. the number of cells analyzed and experiments performed is provided in the figure legends. Abbreviations: AA, antimycin A;
GLC, glucose; Km,V1, affinity (Km) of GLC uptake; Km,V2, affinity (Km) of GLC consumption; LAC, lactate; PA, piericidin A; SD, standard deviation;
V1,max, maximal rate (Vmax) of GLC uptake; V2,max, maximal rate (Vmax) of GLC consumption.
LAC production was measured during 60–90 min in three independent experiments. Routine O2 consumption and P/O ratio were determined in four inde-
pendent experiments. Total ATP after 24 h incubation with vehicle, PA, or AA was measured in three independent experiments, performed in duplo.
aMeasured under conditions of IAA-blocked GLC consumption.
bMeasured under conditions of CytoB-blocked GLC uptake.
cAverage C2C12 cell volume equaled 2.1  10125 0.4  1012 (SD) L (n ¼ 14 cells).
dAssuming a negligible magnitude for V5.
1378 Liemburg-Apers et al.previously used for quantitative prediction of Glut1-medi-
ated GLC influx in HepG2 cells (22):
V1 ¼ Fluxout/in
¼ V1;max 
½GLCext  ½GLCc
  Km;V1
Km;V1 þ ½GLCext
  Km;V1 þ ½GLCc
; (4)with V1,max being the measured maximal value of V1 (Table
1, A1; in mM/min), Km,V1 the measured affinity (Table 1, A1;
in mM), [GLC]ext the extracellular free GLC concentration
(in mM) and [GLC]c the cytosolic free GLC concentration
(in mM). We modeled cytosolic GLC consumption (V2)
using a Michaelis-Menten equation (42) that quantitatively
predicted HK-mediated GLC consumption in HepG2
cells (33):
V2 ¼ V2;max  ½GLCc
Km;V2 þ ½GLCc
; (5)Biophysical Journal 109(7) 1372–1386with V2,max being the measured maximal value of V2
(Table 1, A2; in mM/min), Km,V2 the affinity (in mM), and
[GLC]c the cytosolic free GLC concentration (in mM).
Under conditions that GLC influx is blocked, the rate at
which [GLC]c drops will reflect maximal HK action (see
above) so we used a Km,V2 value of 60 mM (Table 1, A2)
as described in the literature (21,43).Parameter optimization and validation of the
mathematical model
Using the experimental parameter values for V1 and V2
(Table 1) we performed a set of explorative simulations
for the vehicle condition at 2 mM [GLC]ext. This default
model quantitatively matched (not shown) the experimental
data obtained in vehicle-, PA-, and AA-treated cells, with
respect to maximal rate of [GLC]c decrease. This suggests
that the kinetic parameters measured for V2 were correct
for all three conditions. However, the default model
FIGURE 4 Effect of mitochondrial inhibition on
cellular glucose consumption kinetics. (A) Inhibi-
tion of the GLC uptake flux (V1) allows analysis
of GLC consumption (V2). (B) Typical glucose
consumption experiment in cells treated with
vehicle, PA, or AA for 30 min. (C) Average value
(5SD) of resting [GLC]c for 2 mM [GLC]ext in
the absence of CytoB for vehicle-, PA-, or AA-
treated cells (D) The average value (5SD) of the
maximal rate of linear decrease upon cytoB addi-
tion in (B). V2 (n¼ 20 cells; N¼ 4 independent ex-
periments). N.s. not significant. To see this figure
in color, go online.
Glucose Flux and Mitoenergetic Function 1379predicted a much lower steady-state [GLC]c (i.e.,
0.02 mM) than the experimental value (0.49 mM) (Table 1,
A3). To gain insight into why the predicted steady-state
[GLC]c was much lower, the V1 parameters (i.e., Km,V1,
Km,V2 V1,max, V2,max) were manually varied in the default
model to fit the experimental steady-state [GLC]c. This
revealed that only when V1,max was increased (i.e.,
from 0.32 to 1.86 mM/min), the predicted steady-state
[GLC]c matched its experimental value. Also, for the PA-
and AA-treated condition, the steady-state [GLC]c pre-
dicted by the default model was too low (Table 1, A3).
This discrepancy disappeared when V1,max was increased
from 2.8 to 4.2 mM/min (PA-treated cells) and from
2.9 to 4.8 mM/min (AA-treated cells). In this way,
optimal models were obtained (Table 1, B). Upon simu-
lating the FLII calibration procedure, the optimal model
correctly predicted the experimental calibration curve
(Supporting Material B2 and Fig. S5, A and B). The too
low V1,max values reported in our experiments might be
because the rate of GLC uptake was determined under con-
ditions of virtually zero [GLC]c (zero-trans condition;
(44)). This would lead to an underestimation of V1,max
because [GLC]c stimulates Glut-mediated GLC influx by
a mechanism called trans-acceleration (45,46). Indeed(Fig. S4, A and B), the maximal rate of [GLC]c increase
was much higher when [GLC]c equaled 0.4 mM (i.e.,
when GLC uptake was trans-accelerated) than when
[GLC]c was virtually zero (zero-trans condition). In this
sense, the model-predicted underestimation of V1,max in
our experiments is very likely due to the use of zero-trans
conditions.Model prediction of steady-state GLC uptake and
consumption
In a first set of simulations we used the optimal model to
simulate the experiment in Fig. 4 B. Model predictions
(Fig. 5 A) quantitatively matched the experimental data ob-
tained in vehicle-, PA-, and AA-treated cells, with respect to
resting [GLC]c (Fig. 4 C) and maximal rate of [GLC]c
decrease (Fig. 4 D). We then simulated the experiment in
Fig. 2 E, to predict the steady-state values of V1 and V2
(Fig. 5 B). In the presence of 2 mM [GLC]ext, V1 and V2
steady-state values (i.e., when V1 ¼ V2 ¼ Vsteady-state)
increased from 0.60 mM/min (vehicle) to 1.14 mM/min
(PA) to 1.50 mM/min (AA), without significantly affecting
steady-state [GLC]c (Fig. 4 C). To quantify the effect of
V1 and V2 upon the overall steady-state GLC flux weBiophysical Journal 109(7) 1372–1386
FIGURE 5 A minimal model of glucose uptake
and consumption in C2C12 myoblasts. (A)
[GLC]c dynamics predicted by the optimal models
mimicking the experiments in Fig. 4 B for
vehicle-, PA-, and AA-treated cells. Glucose influx
(V1) was set to zero to simulate Glut inhibition by
CytoB. Both resting [GLC]c (y axis) and maximal
linear rate of [GLC]c decrease (numerals) were
predicted correctly. (B) Simulated experiment of
Fig. 2 E to predict the steady-state values (nu-
merals) of GLC influx (V1; dotted lines) and con-
sumption (V2; continuous lines) in vehicle-, PA-,
and AA-treated cells. Glucose influx (V1) was set
to zero to simulate Glut inhibition by CytoB. SS
indicates the steady-state situation. (C) Flux varia-
tion as a function of V1,max and V2,max. The steady-
state flux at 2 mM GLCext was predicted for
different values of V1,max (left panel) and V2,max
(right panel). Arrows mark the Vmax value in the
respective models. (D) Flux control coefficients
for V1 and V2 in (C) (see Results for details).
(E) Schematic representation of the various fluxes
(V1, V2, V3, V4, V5, V6, V7; see Results and Discus-
sion for details). (F) Comparison between the pre-
dicted single-cell LAC production flux (x axis) and
measured average (5SD) of LAC production flux
(y axis) in cells treated with vehicle, PA, or AA in
HT buffer containing 2 mM GLC (N ¼ 3 indepen-
dent experiments). A linear equation was used for
fitting (R2 ¼ 0.90; slope ¼ 1.49 5 0.29; dotted
lines indicate 95% confidence limits). To see this
figure in color, go online.
1380 Liemburg-Apers et al.calculated flux control coefficients in the vehicle-, PA- and
AA- model (Fig. 5, C and D). This was performed by deter-
mining the steady-state GLC flux values at various magni-
tudes of V1,max or V2,max (27,47). The arrows in Fig. 5 C
indicate the values of V1,max (left panel) and V2,max (right
panel) in the three optimal models. At each arrow we calcu-
lated the derivative to obtain the flux control coefficient (i.e.,
dln(Flux/dVmax) ¼ [dFlux/dVmax]  [Vmax/Flux]). For all
three steady-state conditions, the flux control coefficient
was much larger for V2 than for V1 (Fig. 5 D), showing
that the steady-state GLC flux is primarily determined by
the steady-state value of V2.Model prediction of steady-state LAC production
Mitochondrial O2 consumption was fully blocked in inhibi-
tor-treated cells (Fig. S3). This suggests (Fig. 5 E) that theBiophysical Journal 109(7) 1372–1386rate of mitochondrial PYR entry (V5) is close to zero and
that PYR (generated by glycolysis at a rate V3) is converted
into LAC at a rate V4 and subsequently released by the cells
at a rate V7. Although IAA did not alter cytosolic pH, PA-,
and AA-treatment acidified the cytosol to a similar extent
(Fig. S2 C). Of importance, this acidification did not affect
the FLII fluorescence signal (Supporting Material B1 and
Fig S2, B–D). Assuming that all consumed GLC is con-
verted into LAC that is transported out of the cell, we
used the predicted Vsteady-state to calculate V7. At 2 mM
[GLC]ext the optimal model predicts (Table 1, B3) that
Vsteady-state equals 1.14 mM/min (PA) and 1.50 mM/min
(AA). Because glycolytic conversion yields two PYR mole-
cules for each GLC molecule that is consumed, the pre-
dicted rates of PYR generation (V3) and LAC release (V7)
equal V3 ¼ V7 ¼ 2$Vsteady-state, yielding 2.3 mM/min (PA)
and 3.0 mM/min (AA). Experimental analysis (using the
FIGURE 6 Analysis of O2 consumption and total cellular ATP levels in
C2C12 myoblasts. (A) Average values (5SE) for routine, leak, maximal
(ETS) and residual respiration (ROX) in C2C12 cells (N ¼ 6 independent
experiments). (B) Predicted balance between glycolytic and mitochondrial
ATP production in vehicle- and inhibitor-treated cells. See Results for
details. (C) Average values (5SE) of total ATP levels in cells treated for
24 h with vehicle, PA, or AA (N ¼ 3 independent experiments). Statistical
significance was assessed using the Kruskal-Wallis test. To see this figure in
color, go online.
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3.7 5 1.1 (SD) fmol/min/cell (vehicle), 8.7 5 1.5 (SD)
fmol/min/cell (PA), and 7.5 5 3.0 (SD) fmol/min/cell
(AA). To compare these experimental values with the pre-
dictions of the mathematical model (which simulates a sin-
gle cell) information about C2C12 myoblast volume is
required. To this end, we first determined the area of FLII-
expressing cells (using the CitrineFRET image), yielding an
average value of 1.2  103 5 0.4  103 (SD) mm2 (n ¼
14 cells). Using data from the literature (48) it was foundthat C2C12 area and volume display a highly linear correla-
tion (Fig. S6). From this correlation we estimated that the
average C2C12 volume in our experiments equaled 2.1 
1012 5 0.4  1012 (SD) L, compatible with a previous
estimate obtained by three-dimensional microscopy anal-
ysis (49). In case of PA-treated cells the measured value
of V7 equaled (8.7 5 1.5 fmol/min/cell)/(2.1  1012 5
0.4  1012 L) ¼ 4.1 5 1.1 mM/min/cell. A similar
calculation yields 1.8 5 0.6 mM/min/cell and 3.5 5
1.6 mM/min/cell for vehicle- and AA-treated cells, respec-
tively. Quantitative comparison of these measured LAC
fluxes with model predictions revealed a linear correlation
(Fig. 5 F). The fitted line did not significantly differ from
y ¼ x (i.e., the latter fell within the 95% confidence limits
of the fitted line), suggesting that the model correctly pre-
dicted LAC fluxes (V7) for vehicle- and inhibitor-treated
cells.Model predictions of steady-state ATP production
Finally, we integrated model predictions and experimental
results to analyze the balance between glycolytic and mito-
chondrial ATP production in C2C12 cells. For vehicle-
treated cells the amount of ATP derived from glycolysis
equaled 2$Vsteady-state (i.e., 1.20 mM/min). To compare
this flux with mitochondrial ATP production, we measured
routine O2 consumption (Fig. 6 A). Following correction
for leak respiration, the ATP-linked O2 consumption rate
equaled 15.4 5 2.7 pmol/s/106 cells. Considering C2C12
cell volume, this yields an ATP-linked O2 flux of 0.43 5
0.08 (SD) mM/min (Table 1, B3). The ATP production
rate was then calculated from this O2 flux using the phos-
phorus/oxygen ratio (P/O ratio). The latter was determined
by measuring the amount of O2 required to convert
220 nmol ADP to ATP in permeabilized cells supple-
mented with PYR and malate (50). This strategy revealed
a P/O ratio of 2.75 0.4 (SD) (Table 1, B3; Fig. S7), mean-
ing that ATP is produced by mitochondria at a rate of
(2.7 5 0.4)  (0.43 5 0.08 mM/min) ¼ 1.2 5 0.2
(SD) mM/min. Therefore, vehicle-treated C2C12 cells
derive 50% of their cellular ATP from glycolysis and
50% from OXPHOS (Fig. 6 B; Table 1, B3). For inhibi-
tor-treated cells we assumed that ATP is exclusively gener-
ated by glycolysis, yielding fluxes of 2.28 mM/min (PA)
and 3.00 mM/min (AA). Therefore, the total steady-
state ATP production flux is virtually identical for vehicle-
and inhibitor-treated cells (Fig. 6 B): 2.39 mM/min
(vehicle, set at 100%), 2.28 mM/min (PA; 95%), and
3.00 mM/min (AA; 126%). In line with these predictions,
24 h treatment with vehicle-, PA and AA did not signifi-
cantly affect the total cellular ATP level (Fig. 6 C; Table 1,
B3) or the total number of cells (data not shown). This sug-
gests that increased steady-state GLC uptake and consump-
tion fully compensates for the loss of mitochondrial ATP
production in PA- and AA-treated cells.Biophysical Journal 109(7) 1372–1386
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This study focuses on gaining a quantitative understanding
of the balance between steady-state GLC uptake/consump-
tion, glycolytic, and mitochondrial ATP production, and
the effect of mitoenergetic dysfunction on this system. We
provide integrated experimental and in silico evidence
that the glycolytic pathway and mitochondria equally
contribute to total ATP production in C2C12 myoblasts.
Acute (30 min) OXPHOS inhibition induced a twofold in-
crease in steady-state GLC uptake and consumption, which
fully compensated for the drop in mitochondrial ATP pro-
duction. Our results suggest a mechanism in which mitoe-
nergetic dysfunction triggers compensatory activation of
the glycolysis pathway, allowing metabolic flexibility.In situ calibration and validation of the FLII GLC
sensor
Predictive mathematical modeling requires a quantitative
measure of [GLC]c. Therefore, we calibrated the emission
ratio of the FLII sensor by incubating the cells with different
[GLC]ext concentrations in the presence of the V2 inhibitor
IAA. The in situ FLII calibration curve displayed Michae-
lis-Menten kinetics and a Km of 1.9 mM, which was 2.7-
fold higher than its in vitro Km value (51). This illustrates
the importance of in situ calibration (52) and demonstrates
that FLII most sensitively reports [GLC]c when [GLC]c is
near 1.9 mM. Of note, discrepancies between in situ and
in vitro Km values are not uncommon, as illustrated by the
eightfold increase in Km for the proteinaceous Ca
2þ sensor
PericamR when expressed in the mitochondrial matrix
(53). We demonstrated that the FLII ratio is not affected
by cytosolic acidification in our experiments, compatible
with previous findings in yeast cultures (51). Taken together,
we provided evidence that the employed calibration proce-
dure and experimental conditions are suited for quantitative
measurement of [GLC]c(t) using the FLII sensor.Quantification of cellular GLC uptake and
consumption
In previous studies cellular GLC uptake (V1) was measured
using a radio-labeled variant of GLC (i.e., 2-deoxy-D-
glucose or 2DG), which inhibits HK and is phosphorylated
by this enzyme (54,55). However, this approach cannot
be used to study the relatively rapid temporal GLC dy-
namics at the (sub)cellular level. In addition, fluorescently
labeled GLC analogs such as 2-(N-(7-nitrobenz-2-oxa-1,3-
diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) and 6-(N-
(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-6-deoxyglucose
(6-NBDG) have been used to quantify V1 (56,57). However,
these GLC analogs display a different affinity for Glut trans-
porters than GLC (58). Here, we experimentally dissected
the contribution of V1 to [GLC]c dynamics, by removingBiophysical Journal 109(7) 1372–1386[GLC]ext and preventing cytosolic GLC consumption (V2)
using IAA. Measurements of zero-trans GLC uptake were
performed by extracellular addition of GLC to cells with
zero GLC on the trans (i.e., intracellular) site. Upon GLC
addition, the rate of change in [GLC]c (i.e., d[GLC]c/dt)
was determined by quantifying the maximal slope of the
calibrated FLII signal. This slope was then used as a mea-
sure of the initial rate of GLC uptake. Because the sum of
V1 and V2 in the absence of IAA is similar to the experi-
mental value of V1 in the presence of IAA, it appears that
IAA does not affect GLC uptake. Q-PCR analysis revealed
that Glut1 is expressed, whereas Glut2, Glut3, and Glut4
transcripts were not detected. This suggests that V1 primar-
ily reflects Glut1-mediated GLC uptake. In vehicle-treated
cells the maximal rate of V1 (V1,max) was 0.32 5
0.05 mM/min and its Km value (Km,V1) equaled 1.4 5
0.3 mM. Similar Km,V1 values (i.e., 0.38–2.00 mM) were re-
ported in previous studies (22,28,44,59), suggesting that our
experimental strategy to determine Km,V1 is valid. The
maximal value of V2 (V2,max) was determined in the pres-
ence of the V1-blocker CytoB (35). Because HK displays
a GLC-affinity of ~60 mM (7,43) it operates (near) it’s
Vmax at the measured [GLC]c concentrations.OXPHOS inhibition stimulates cellular GLC
uptake
30 min treatment with PA or AA did not significantly affect
the affinity of GLC uptake (Km,V1) but induced an eightfold
increase in V1,max, compatible with previous results in
OXPHOS-inhibited cells (9,23,40,60,61). Similar to another
study (62), Q-PCR analysis revealed that inhibitor treatment
did not alter Glut mRNA levels (data not shown). Although
PA and AA are chemically dissimilar and target different
OXPHOS complexes, they equipotentially stimulated GLC
uptake. This suggests that the latter is due to OXPHOS inhi-
bition rather than off-target effects of PA and AA, support-
ing a mechanism in which acute mitochondrial dysfunction
stimulates Glut1-mediated GLC uptake in C2C12 myo-
blasts. A similar phenomenon was induced by extracellular
alkalinization, possibly by modification of Glut cysteine res-
idues (63). However, here we measured that OXPHOS inhi-
bition lowered cytosolic pH and increased extracellular
LAC levels, which argues against involvement of alkaliniza-
tion-induced Glut1 activation. Alternatively, OXPHOS inhi-
bition might induce a drop in ATP level leading to reduced
ATP-induced inhibition of Glut1 activity (64,65). Our re-
sults argue against such a mechanism because 1) they sug-
gest that the drop in OXPHOS-mediated ATP production
is fully compensated for by increased glycolytic activity,
and 2) they demonstrate that total cellular ATP amount is
not significantly reduced in cells treated with OXPHOS in-
hibitors for 24 h. Glut1 activity might also be increased by a
mechanism involving AMP-activated protein kinase, activa-
tion (phosphorylation) of which was linked to stimulation of
Glucose Flux and Mitoenergetic Function 1383GLC transport during OXPHOS inhibition (9,67). Alterna-
tively, Glut1 redox modification and oligomerization were
demonstrated to regulate Glut1 activity (68–71) and the
amount of active Glut1 at the PM might be increased by
stimulation of Glut1 translocation from internal storage ves-
icles to the PM or by activation of PM-localized Glut1 by
OXPHOS inhibition (9–11,13).OXPHOS inhibition stimulates cellular GLC
consumption
OXPHOS inhibition induced a two-fold increase in the
maximal rate of GLC consumption (V1,max). Genomic
expression profiling (http://www.ncbi.nlm.nih.gov/geo/;
GEO accession: GDS2420) suggests that C2C12 myoblasts
express HK isoforms I and II. HK-mediated phosphoryla-
tion of GLC leads to formation of G6P, which allosterically
inhibits HKI and HKII. In case of HKI this inhibition is
antagonized by Pi, whereas the latter activates HKII (72).
This suggests that increased GLC consumption might
be explained by Pi-induced activation of HKII during
OXPHOS inhibition. However, as discussed previously,
our results argue against such a mechanism because glyco-
lytic activity fully compensated for the loss in OXPHOS-
mediated ATP production in PA- or AA-treated cells and
total cellular ATP was not affected after 24 h inhibitor
treatment. GLC consumption might also be increased in
OXPHOS-inhibited cells by activation of glucokinase, a
low-affinity (Km ¼ 8 mM) HK isozyme (73). However:
1) the above expression profiling suggests that glucokinase
is not expressed in C2C12 myoblasts (confirmed in (74)),
and 2) the steady-state resting [GLC]c was 10-fold
lower than the Km of glucokinase in vehicle-treated and
OXPHOS-inhibited cells. In addition to HK activation,
increased GLC consumption likely involves stimulation
of other (glycolytic) enzymes including phosphofructoki-
nase (PFK) and pyruvate kinase. A more detailed analysis
of the mechanism linking OXPHOS inhibition to activation
of GLC uptake and consumption is currently carried out in
our laboratory.A minimal model of cytosolic GLC dynamics
To predict steady-state GLC uptake and consumption
fluxes, we constructed a minimal mathematical model
that consisted of two equations: 1) a reversible Michae-
lis-Menten equation for GLC uptake (V1) and 2) an
irreversible Michaelis-Menten equation for GLC consump-
tion (V2). The GLC uptake equation does not account for
asymmetry (i.e., different kinetic parameters for GLC
influx and efflux) or trans-accelerated transport. The ki-
netic parameters for V1 (Km,V1 and V1,max) and V2
(V2,max) were experimentally determined and included in
the model. In the case of V2, we used a GLC-affinity
(Km,V2) of 60 mM compatible with values previously re-ported for HK and HK-mediated GLC consumption in
C2C12 cells (22,35,43). Initially, the model predicted a
too low steady-state [GLC]c in vehicle- and inhibitor-
treated cells (default model). Manual parameter optimiza-
tion revealed that our experimental strategy systematically
underestimated V1,max, which had to be increased from
0.32 to 1.86 mM/min (vehicle), from 2.8 to 4.20 mM/
min (PA), and from 2.9 to 4.80 mM/min (AA) to generate
quantitatively correct predictions (optimal model). Trig-
gered by these model predictions, we provided experi-
mental evidence suggesting that our experimental method
underestimates the rate of GLC uptake due to a lower
[GLC]c. Of importance, the adjusted V1,max values in the
optimal model fell within a similar range as those reported
for Glut1-mediated GLC entry in HepG2 cells (i.e.,
7.2 mM/min; (22)).Predicting the glycolytic flux at steady-state
Model predictions yielded a steady-state value of V1¼ V2¼
Vsteady-state of 0.60 mM/min in vehicle-treated cells.
Vsteady-state was twofold higher in PA- and AA-treated cells.
Under all three conditions V2 displayed the largest flux con-
trol coefficient (i.e., 0.6–0.8), indicating that the GLC flux
was primarily determined by the steady-state value of V2.
The flux control coefficient of V1 was below 0.1 for all three
conditions. In comparison, the flux control coefficient of
GLC uptake upon oxygen consumption ranged between
0.3 and 0.5 and increased upon lowering GLCext in Trypano-
soma brucei (75). In PA- and AA-treated cells mitochon-
drial O2 consumption was fully blocked, meaning that
mitochondrial PYR entry (V5) is negligible. Under these
conditions, we assumed that all the GLC (consumed at
rate Vsteady-state) is converted into LAC and released from
the cell at a predicted rate V7. The latter prediction agreed
with LAC release measurements, supporting the validity
of our minimal model and suggesting that the contribution
of alternative pathways branching off or feeding into to
the glycolytic pathway is relatively low. Interestingly, also
in the absence of inhibitors (i.e., when V5 was not zero)
the predicted V7 was close to the measured LAC release.
This strongly suggests that the magnitude of steady-state
mitochondrial PYR uptake (V5) is much smaller than the
rate of PYR-to-LAC conversion (V4) and subsequent LAC
release (V7) in vehicle-treated cells. Because the LAC
release predicted using Vsteady-state matched with the experi-
mental LAC release rate it appears that Vsteady-state is a good
measure of GLC flux. The fact that the measured LAC
release was higher than the predicted LAC release for all
three conditions might be due to hydrolysis of glycogen to
G6P, thereby increasing V3 and V7. In addition, we cannot
exclude that glucogenic amino acids contribute to PYR
and LAC production in our experiments. For analysis of
the glycolytic flux, our strategy provides an alternative to
measurement of the extracellular acidification rate, whichBiophysical Journal 109(7) 1372–1386
1384 Liemburg-Apers et al.might not always provide a reliable estimate of glycolytic
flux (76).Balancing glycolytic and mitochondrial ATP
production
Analysis of ATP-linked mitochondrial O2 consumption
and P/O ratio in vehicle-treated cells suggested that ATP
was generated by the OXPHOS system at a rate of
1.20 mM/min. Because Vsteady-state also equaled 1.20 mM/
min, thismeans that under vehicle conditions 50% of the total
ATP is generated by glycolysis and 50% by OXPHOS. As a
consequence, a twofold increase in Vsteady-state under condi-
tions of OXPHOS inhibition fully compensates for the loss
in OXPHOS-mediated ATP production. Indeed, model pre-
dictions suggested that the total cellular ATP production
rate under steady-state conditions equaled 100% (vehicle),
95% (PA), and 126% (AA). Following 24 h treatment, total
cellular ATP content and total cell number were similar for
vehicle- and inhibitor-treated cells. This is compatible with
a mechanism in which glycolytic ATP production fully com-
pensates for the loss in mitochondrial ATP production. A
similar lack of effect on total ATP content was demonstrated
in MEFs from NDUFS4/ mice with isolated CI deficiency
(4) and in fully glycolytic skin fibroblasts treated for 72 hwith
the CI inhibitor rotenone (77). C2C12 myoblasts displayed
a relatively high glycolytic and low mitochondrial PYR
influx. This allowed a twofold increase in glycolytic flux
to fully compensate for the lack of mitochondrial ATP
production in PA- and AA-treated cells. In this context, cells
displaying a more oxidative metabolism would likely require
a larger increase in glycolytic flux to meet their overall ATP
demand.CONCLUSIONS
By combining experiments and mathematical modeling we
demonstrate here that mitoenergetic dysfunction triggers a
rapid compensatory increase in steady-state GLC uptake
and consumption in C2C12 myoblasts. This mechanism
maintains the balance between cellular ATP supply and de-
mand, thereby preventing energy crisis in cells in which
mitochondrial ATP generation is compromised.SUPPORTING MATERIAL
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